Association of Fas -1377 G/A polymorphism with susceptibility to cancer

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Geng, Peiliang ^a   Li, Jianjun ^a   Ou, Juanjuan ^a   Xie, Ganfeng ^a   Wang, Ning ^a   Xiang, Lisha ^a   Sa, Rina ^a   Liu, Chen ^a   Li, Hongtao ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; FAS ANTIGEN; GUANINE; FAS PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FAS GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MOUTH CANCER; NUCLEIC ACID BASE SUBSTITUTION; STOMACH CANCER; UTERINE CERVIX CANCER; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; NEOPLASM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD95; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84895884119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088748     Document Type: Article

References (47)

1. Bredberg A (2011) Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer 117: 440-445.
2. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
3. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4: 850-860. (Pubitemid 39472952)
4. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
5. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
6. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, et al. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63: 4327-4330. (Pubitemid 36950998)
7. Kim HJ, Jin XM, Kim HN, Lee IK, Park KS, et al. (2010) Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29: 619-624.
8. Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, et al. (2006) Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54: 303-308. (Pubitemid 44634149)
9. Gormus U, Ergen A, Yaylim-Eraltan I, Yilmaz H, Turna A, et al. (2007) Fas-1377 A/G polymorphism in lung cancer. In Vivo 21: 663-666. (Pubitemid 47232669)
10. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462.
11. Raff M (1998) Cell suicide for beginners. Nature 396: 119-122.
12. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF, et al. (2003) Apoptosis and lung cancer: a review. J Cell Biochem 88: 885-898. (Pubitemid 36337033)
13. Hajra KM, Liu JR (2004) Apoptosome dysfunction in human cancer. Apoptosis 9: 691-704. (Pubitemid 40941198)
14. Li LH, Li WX, Wu O, Zhang GQ, Pan HF, et al. (2009) Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis. Mol Biol Rep 36: 2047-2052.
15. Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14: 821-822.
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: p. 557-560. (Pubitemid 37088507)
18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
19. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
20. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
21. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, et al. (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28: 2548-2551. (Pubitemid 350238957)
22. Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, et al. (2007) Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol 29: 815-821. (Pubitemid 350307702)
23. Zhang B, Sun T, Xue L, Han X, Zhang B, et al. (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28: 1067-1073. (Pubitemid 47072192)
24. Wang W, Zheng Z, Yu W, Lin H, Cui B, et al. (2012) Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 3: 625-628.
25. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, et al (2013) Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One 8: e53075.
26. Kang S, Dong SM, Seo SS, Kim JW, Park SY (2008) FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180: 1-5. (Pubitemid 350199691)
27. Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, et al. (2005) Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 99: 113-118.
28. Sun T, Zhou Y, Li H, Han X, Shi Y, et al. (2005) FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202: 967-974. (Pubitemid 41396896)
29. Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, et al. (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29: 2147-2152.
30. Zhang X, Miao X, Sun T, Tan W, Qu S, et al. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42: 479-484. (Pubitemid 40847235)
31. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, et al. (2010) Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 25: 555-561.
32. Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, et al. (2011) Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 12: 112.
33. Li C, Larson D, Zhang Z, Liu Z, Strom SS, et al. (2006) Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16: 253-263.
34. Zhang H, Sun XF, Synnerstad I, Rosdahl I (2007) Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 13: 233-237.
35. Wang LH, Ting SC, Chen CH, Tsai CC, Lung O, et al. (2010) Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med, 2010. 39(2): 155-161.
36. Karimi MY, Kapoor V, Sharma SC, Das SN (2013) Genetic polymorphisms in FAS (CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral carcinoma: gene-gene interactions in high-risk Indians. Cancer Invest 31: 1-6.
37. Krippl P, Langsenlehner U, Renner W, Köppel H, Samonigg H (2004) Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1478-1479. (Pubitemid 39429673)
38. Li C, Wu W, Liu J, Qian L, Li A, et al. (2006) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 16: 245-251.
39. Sun T, Miao X, Zhang X, Tan W, Xiong P, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1030-1036. (Pubitemid 39162646)
40. Yang M, Sun T, Wang L, Yu D, Zhang X, et al. (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14: 3230-3236.
41. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, et al. (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12: 5596-602. (Pubitemid 44497278)
42. Zhu J, Qin C, Wang M, Yan F, Ju X, et al. (2010) Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 49: 810-817.
43. Cao Y, Miao XP, Huang MY, Deng L, Lin DX, et al. (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49: 944-950.
44. Lu MM, Ye QL, Feng CC, Yang J, Zhang T, et al. (2012) Association of FAS gene polymorphisms with systemic lupus erythematosus: A case-control study and meta-analysis. Exp Ther Med 4: 497-502.
45. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2012) Associations between the FAS -670 A/G and -1,377 G/A polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis. Mol Biol Rep 39: 10671-9.
46. Xiang N, Li XM, Wang GS, Tao JH, Li XP (2013) Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 40: 407-415.
47. Qiu LX, Shi J, Yuan H, Jiang X, Xue K, et al. (2009) FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet 125: 431-435.